PHKA2

Phosphorylase b kinase regulatory subunit alpha, liver isoform · P46019 · PHKA2 on Sugi Atlas →

282 patent compounds predicted against PHKA2, 250 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Hydrochloric Acid (SCHEMBL8321621)	1.00	3/20
SCHEMBL8323028	1.00	3/20
Hydrochloric Acid (SCHEMBL8323337)	1.00	3/20
Hydrochloric Acid (SCHEMBL8323340)	1.00	3/20
Hydrochloric Acid (SCHEMBL8323341)	1.00	3/20
SCHEMBL8325893	1.00	3/20
SCHEMBL8325899	1.00	3/20
SCHEMBL8325901	1.00	3/20
SCHEMBL30569343	1.00	3/20
SCHEMBL8325755	0.84	3/20
SCHEMBL8325756	0.84	3/20
SCHEMBL8325761	0.84	3/20
SCHEMBL8328590	0.84	3/20
Hydrochloric Acid (SCHEMBL8325486)	0.83	3/20
Hydrochloric Acid (SCHEMBL8325487)	0.83	3/20
Hydrochloric Acid (SCHEMBL8325673)	0.83	3/20
Hydrochloric Acid (SCHEMBL8325674)	0.83	3/20
Hydrochloric Acid (SCHEMBL8322489)	0.81	3/20
Hydrochloric Acid (SCHEMBL8326455)	0.81	3/20
Hydrochloric Acid (SCHEMBL8326458)	0.81	3/20

Clinical trials — most relevant to PHKA2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis	PHASE2	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia	PHASE2	COMPLETED
A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease	PHASE2	COMPLETED
PKC412 and 5-Azacytidine	PHASE1/PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors	PHASE1	COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors	PHASE1	COMPLETED
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)	nan	COMPLETED
The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia	nan	RECRUITING
Effect Of Scaling and Root Planning on ALP in Saliva and GCF In Periodontitis Patients Compared With Healthy Individuals	nan	UNKNOWN
United States Hypophosphatasia Molecular Research Center	nan	COMPLETED
Characteristics of Hypophosphatasia in Adult Patients in Rheumatology	nan	UNKNOWN
Planetary Habitat Simulation: Bone Metabolism Studies	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Study of Autoimmune Lymphoproliferative Syndrome (ALPS)	nan	RECRUITING
Calciotropic Effects After HCG Stimulation Test	nan	COMPLETED
Characteristics of Hypophosphatasia in Adult Patients in Rheumatology and Their Value in Developing an Algorithm to HPP-diagnosis - the COHIR Multi-center Study	nan	RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Pathophysiology of Paget's Disease of Bone	nan	COMPLETED
The Role of Vitamin K2 in Preventing Glucocorticoid-Induced Bone Loss in Children With Nephrotic Syndrome	nan	RECRUITING
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN
Tissue-nonspecific Alkaline Phosphatase in Phosphate and Pyrophosphate Homeostasis.	nan	COMPLETED
Genetic Mapping of Atherogenic Lipoprotein Phenotypes	nan	COMPLETED
The Role Of FGF23, Klotho, And Sclerostin In Kidney Stone Formers	nan	UNKNOWN
IVF Outcome in Polycystic Ovary Syndrome Patients	nan	UNKNOWN
Studying Phosphorus Metabolism	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PHKA2 binder may also engage these)

Protein	Name	Similarity
Q8BWJ3	—	1.000	Q8BWJ3 →
PHKB	Phosphorylase kinase beta subunit	1.000	landscape →
P46018	—	1.000	P46018 →
Q64649	—	1.000	Q64649 →
Q7TSH2	—	1.000	Q7TSH2 →
PHKA1	Phosphorylase b kinase regulatory subunit alp	1.000	landscape →
Q9VLS1	—	0.999	Q9VLS1 →
Q9W6R1	—	0.998	Q9W6R1 →
Q18892	—	0.998	Q18892 →
P03541	—	0.997	P03541 →
P19239	—	0.997	P19239 →
P31924	—	0.997	P31924 →
B4UT01	—	0.997	B4UT01 →
O46431	—	0.997	O46431 →
P35671	—	0.997	P35671 →
Q8BD31	—	0.997	Q8BD31 →
P12798	—	0.997	P12798 →
P18688	—	0.997	P18688 →
P04712	—	0.997	P04712 →
P31922	—	0.996	P31922 →
O84702	—	0.996	O84702 →
Q77GW1	—	0.996	Q77GW1 →
P34335	—	0.996	P34335 →
P22047	—	0.996	P22047 →
Q9W391	—	0.996	Q9W391 →
O49845	—	0.996	O49845 →
P17595	—	0.996	P17595 →
P0DJR3	—	0.996	P0DJR3 →
Q00159	—	0.996	Q00159 →
H6TFZ4	—	0.996	H6TFZ4 →